Market analysis of blood lipid regulating drugs: when did pivastatin, a young generation, resist?

Source: pharmaceutical economic daily July 20, 2015: pivastatin is a high-cost cholesterol lowering drug, which has not been listed in the national medical insurance drug catalog, only entered 10 provinces and cities Pivastatin tablets have been on the market for more than six years in China What's the current performance? Although the growth rate is gratifying, but because the base is too small, it is a little difficult to impact high sales The author predicts that the market of pivalastatin tablet prescription drugs in domestic sample hospitals will break through the RMB 100 million mark in 2016 At present, the global market structure of statins for cholesterol lowering drugs is still known as atorvastatin, rosuvastatin, simvastatin, pravastatin, fluvastatin, lovastatin and pivastatin It is understood that the innovative lipid-lowering drug PCSK9 inhibitor is still in progress, and Sanofi's praluent and Amgen's repatha will take the lead in the market According to the annual report data released by the manufacturers of global lipid regulating drugs, the global statins market in 2014 showed a continuous decline under the influence of the weak development of new drug market and the post Lipitor era According to IMS data, in 2014, the global sales of original brand drugs of statins totaled 11 billion US dollars, down 5.96% year on year, only 46% of the peak value of 23.8 billion US dollars in 2006 See http://news.pharmnet.com.cn/news/2015/07/17/424341.html for details